CA Patent

CA3185209A1 — Gas41 inhibitors and methods of use thereof

Assigned to University of Michigan System · Expires 2021-01-27 · 5y expired

What this patent protects

Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.

USPTO Abstract

Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.

Drugs covered by this patent

rucaparib-camsylate (RUCAPARIB CAMSYLATE)

Patent Metadata

Patent number: CA3185209A1
Jurisdiction: CA
Classification: —
Expires: 2021-01-27
Drug substance claim: No
Drug product claim: No
Assignee: University of Michigan System
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.